Pharmaceutical Executive
The Australian government has an unusual plan for reducing prescription drug costs: enlist the help of pharma sales reps to explain the country's pharmaceutical benefits scheme (PBS) prescribing requirements to doctors.
The Australian government has an unusual plan for reducing prescription drug costs: enlist the help of pharma sales reps to explain the country's pharmaceutical benefits scheme (PBS) prescribing requirements to doctors.
The PBS has subsidized drug prices for more than 50 years, but medication costs have escalated recently, partly as a result of inappropriate prescribing. The Australian Pharmaceutical Manufac-turers Association (APMA) proposed the idea because it believes its representatives are well placed to explain the restric-tions the PBS places on their company's products. The government also announced several other measures aimed at reducing PBS expenditures by a total of A$1.9 billion during the next four years.
One measure increases the amount patients must pay for each prescription by A$1 for concessional cardholders to A$6.20 for general patients. That measure alone may save A$1.1 billion over the four-year period. Yet, APMA slammed the initiative, claiming it will put essential medicines out of many patients' reach. Its research shows, in fact, that much of the savings will come from patients' inability to afford their prescriptions. (See "Total Savings to Government.")
Total Savings to Government
APMA is also unhappy about the government's agreement with generics manufacturers, which will make doctors' automatic prescribing systems default to the generic version unless the doctor overrides it. In return, generics manufacturers will reduce prices.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.